Assessment of Immunomodulatory Therapies in Regenerative Medicine: Clinical Trials Evaluating Safety and Efficacy

Jyoti M.(1.Chiplunkar Laboratory, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai, India)
Madamin Joglekar(2.Stem Cells and Diabetes Section, Laboratory 12, National Centre for Cell Science, Pune, India)
Anandwardhan Shork(2.Stem Cells and Diabetes Section, Laboratory 12, National Centre for Cell Science, Pune, India)

Abstract

This research study aims to assess the safety and efficacy of immunomodulatory therapies in regenerative medicine through a comprehensive analysis of clinical trials. A systematic review of relevant literature will be conducted to identify clinical trials evaluating different immunomodulatory therapies in the context of regenerative medicine. Data regarding treatment protocols, patient demographics, adverse events, and therapeutic outcomes will be collected and analyzed. Statistical methods will be employed to assess the safety profile and efficacy of immunomodulatory therapies in promoting tissue regeneration and repair. The findings from this study will provide valuable insights into the clinical utility of immunomodulatory therapies in regenerative medicine and inform future research directions in this field.

References

Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007;262(5):509-525. doi:10.1111/j.1365-2796.2007.01844.x

English K, French A, Wood KJ. Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell. 2010;7(4):431-442. doi:10.1016/j.stem.2010.09.009

Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726-736. doi:10.1038/nri2395

Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy. 2013;15(9):1054-1061. doi:10.1016/j.jcyt.2013.02.010

Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32(3):252-260. doi:10.1038/nbt.2816

Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905

Friedenstein AJ, Piatetzky S, II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol. 1966;16(3):381-390.

Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147. doi:10.1126/science.284.5411.143

Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641-650. doi:10.1002/jor.1100090504

Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20(1):14-20. doi:10.1038/mt.2011.211

Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol. 2011;6:457-478. doi:10.1146/annurev-pathol-011110-130230

Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA. Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells. 2011;29(6):913-919. doi:10.1002/stem.643

Matthay MA, Goolaerts A, Howard JP, Lee JW. Mesenchymal stem cells for acute lung injury: preclinical evidence. Crit Care Med. 2010;38(10 Suppl):S569-S573. doi:10.1097/CCM.0b013e3181f08a7f

Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31(10):890-896. doi:10.1016/s0301-472x(03)00110-3

Li Y, Lin F. Mesenchymal stem cells are injured by complement after their contact with serum. Blood. 2012;120(17):3436-3443. doi:10.1182/blood-2012-03-416710

Raffaghello L, Bianchi G, Bertolotto M, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008;26(1):151-162. doi:10.1634/stemcells.2007-0416

Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol. 2005;289(1):F31-F42. doi:10.1152/ajprenal.00007.2005

Parekkadan B, van Poll D, Suganuma K, et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One. 2007;2(9):e941. doi:10.1371/journal.pone.0000941

Walker PA, Shah SK, Jimenez F, et al. Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: preserving the blood brain barrier via an interaction with splenocytes. Exp Neurol. 2010;225(2):341-352. doi:10.1016/j.expneurol.2010.07.011

Moll G, Alm JJ, Davies LC, et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells. 2014;32(9):2430-2442. doi:10.1002/stem.1718

DOI: http://dx.doi.org/10.26549/ahpr.v5i1.15928